ABSTRACT The effect of thrombolysis in acute myocardial infarction on enzymatic infarct size, left ventricular function, and early mortality was studied in subsets of patients in a randomized trial. Early thrombolytic therapy with intracoronary streptokinase (152 patients) or with intracoronary streptokinase preceded by intravenous streptokinase (117 patients) was compared with conventional treatment (264 patients). All 533 patients were admitted to the coronary care unit within 4 hr after onset of symptoms indicative of acute myocardial infarction. Four hundred eighty-eight patients were eligible for this detailed analysis, and 245 of these were allocated to thrombolytic therapy and 243 to conventional treatment. Early angiographic examinations were performed in 212 patients allocated to thrombolytic therapy. Patency of the infarct-related artery was achieved in 181 patients (85%). Enzymatic infarct size, as measured from cumulative a-hydroxybutyrate dehydrogenase release, was smaller in patients allocated to thrombolytic therapy (median 760 vs 1170 U/liter in control patients, p = .0001). Left ventricular ejection fraction measured by radionuclide angiography before discharge from the hospital was higher after thrombolytic therapy (median 50% vs 43% in control patients, p = .0001). Three month mortality was lower in patients allocated to thrombolytic therapy (6% vs 14% in the control group, p = .006). With the use of multivariate regression analysis, infarct size limitation, improvement in left ventricular ejection fraction, and three month mortality were predicted by sum of the ST segment elevation, time from onset of symptoms to admission, and Killip class at admission. Thrombolysis was most effective in patients admitted within 2 hr after onset of symptoms and in patients with a sum of ST segment elevation of 1.2 mV or more. On the other hand, no beneficial effects of streptokinase on enzymatic infarct size, left ventricular function, or mortality were observed in the subset of patients with a sum of ST segment elevation of less than 1.2 mV who were admitted between 2 and 4 hr after onset of symptoms. Circulation 74, No. 6, 1379No. 6, -1389No. 6, , 1986 IN APPROXIMATELY 80% to 90% of patients with acute myocardial infarction, intracoronary infusion of streptokinase given in the first hours after onset of chest pain leads to thrombolysis and recanalization of the occluded coronary artery. 1-3
IN APPROXIMATELY 80% to 90% of patients with acute myocardial infarction, intracoronary infusion of streptokinase given in the first hours after onset of chest pain leads to thrombolysis and recanalization of the occluded coronary artery. [1] [2] [3] angiographically proven obstruction, without major complications. The high patency rate after thrombolysis was associated with limitation of infarct size, higher left ventricular ejection fraction (LVEF), and improved survival in comparison with these variables in conventionally treated patients. The design of this study, clinical course in the hospital, complications of early catheterization, limitation of enzymatic infarct size, and improvement in left ventricular function and survival during the follow-up period have been described elsewhere. [4] [5] [6] [7] The aim of the present analysis was to define subsets of patients that benefitted most from early recanalization. Special attention was paid to patient characteristics available early after hospital admission, such as history, the delay between onset of symptoms and admission, the extent of myocardial ischemia as reflected by the sum of ST segment elevation (EST) on the electrocardiogram (ECG), and the hemodynamic state of each patient.
Patient selection and methods
Patients were eligible for the trial if they were admitted to one of the participating coronary care units within 4 hr after the onset of chest pain and with electrocardiographic signs typical of acute myocardial infarction: ST segment elevation of at least 0.1 mV in one or more extremity leads or that of at least 0.2 mV in one or more precordial leads, or ST segment depression of at least 0.2 mV in one or more precordial leads, compatible with posterior wall infarction.4 Exclusion criteria were age over 70 years, previous treatment with streptokinase, recent trauma (including prolonged resuscitation), enhanced risk of bleeding, pregnancy, bypass surgery of a vessel corresponding to the infarct location, and mental confusion that precluded the patient from giving informed consent. Patients who met the inclusion criteria were registered by a central telephone answering service and were allocated either to thrombolytic therapy or to conventional treatment. Informed consent was obtained from patients allocated to thrombolytic therapy only. Patients who refused consent or patients in whom thrombolytic therapy was withheld for other reasons received conventional treatment, but were included in the analysis according to original treatment allocation. 8 Early coronary angiographic examinations were performed only in patients allocated to thrombolytic therapy, after informed consent had been obtained ( figure 1) . If the infarctrelated coronary artery appeared to be occluded, intracoronary streptokinase was given at a rate of 4000 U/min, until all visible clots had disappeared or the total of 250,000 U of streptokinase had been given. In the second part of the study cardiac catheterization was preceded by infusion of 500,000 U of streptokinase over 20 min, administered intravenously to reduce treatment delay. After catheterization patients allocated to thrombolytic therapy were treated according to the same treatment protocol as the control group. Serum a-hydroxybutyrate dehydrogenase (HBDH) levels were determined upon admission, every 12 hr for 2 days, and then daily up to the fifth day. Cumulative HBDH release was calculated from these data as described before.9' 10 Radionuclide angiography was performed 1 to 3 days after admission, before discharge, and again after 3 months. Cardiac catheterization was offered to all patients before discharge. All patients were followed at the outpatient clinic for at least 1 year after admission.
For identification of subgroups the following data, available at the moment of randomization, were considered: (1) history (age, gender, previous myocardial infarction, history of angina pectoris, time from onset of symptoms to admission), (2) results of physical examination (heart rate, blood pressure, Killip class), (3) electrocardiographic findings (location of the infarct, extent of ST segment elevation and depression).
All ECGs were reviewed independently by two experienced
cardiologists. Consensus about the interpretation was always reached. hundred sixty-four patients were allocated to conventional treatment and 269 to thrombolytic therapy; 152 of these were allocated to treatment with intracoronary streptokinase and 117 to intracoronary streptokinase preceded by intravenous streptokinase.
Forty-five patients were excluded from the present analysis because the ECG obtained at admission to the trial could not be interpreted in accordance with the definitions presented above. These patients were evenly distributed between the two treatment groups. Nineteen patients were excluded because they did not have the required amount of ST segment elevation on the ECG and 17 were excluded because they had only ST segment depression. Two patients with third-degree atrioventricular block and ventricular escape rhythm, one patient with left bundle branch block, and one patient with preexcitation due to an abnormal atrioventricular conduction pathway were also excluded. The ECGs from five patients could not be retrieved for review. Table 1 lists the baseline and follow-up data from the patients admitted to the trial, including 488 patients included in this analysis and 45 patients excluded. One year follow-up was complete in all patients. All baseline characteristics were equally distributed between the two treatment groups. Patients allocated to thrombolytic therapy had lower cumulative HBDH release, higher LVEFs as measured by radionuclide and contrast angiography, and improved survival compared with patients allocated to conventional treatment.t 6 From here on results are presented for patients included in this analysis only.
Early angiographic examinations were performed in 212 patients allocated to thrombolytic therapy (figure 2). Among patients treated with intracoronary streptokinase only, the infarct-related vessel was patent on the first angiogram in 22 of 118 patients (19%) and patency was achieved in 100 patients (85%). In the group pretreated with intravenous streptokinase initial vessel patency was observed in 39 of 94 (41%), and final patency was achieved in 81 patients (86%).
Elfect of thrombolytic therapy on enzymatic infarct size. Enzymatic infarct size was measured by cumulative HBDH release in the first 72 hr after onset of symptoms in 414 patients. To eliminate bias caused by missing data, infarct size was estimated in 74 patients. Twenty-seven patients who died within 72 hr all had extensive myocardial infarction and were assigned to the largest infarct category and 10 patients without significant enzyme elevation were assigned to the group with the smallest infarct size. In 29 patients infarct size was estimated from cumulative HBDH release in the first 48 hr, and in eight patients it was estimated from cumulative creatine kinase release. group. For patients admitted to the hospital after onset of symptoms there was no relationship between duration of symptoms and enzymatic infarct size in the control group, but limitation of infarct size by thrombolytic therapy decreased as the delay between onset of symptoms and admission lengthened. Limitation of infarct size was greater in patients with an anterior infarct (480 U/liter) than in patients with an inferior infarct (330 U/liter). Patients in Killip class III or IV at admission had extensive myocardial infarction and in these patients there was a substantial limitation of enzymatic infarct size by thrombolytic therapy. Elfect of thrombolytic therapy on left ventricular function. LVEF was measured by radionuclide angiography 1 to 3 days after admission, before discharge, and again after 3 months, and by contrast angiography 10 to 40 days after admission. Radionuclide angiographic LVEF before discharge was used to assess the improvement in left ventricular function induced by streptokinase (336 patients). If data on radionuclide angiographic LVEF before discharge were missing, measurements obtained after 3 months (56 patients), after 1 to 3 days (62 patients) or of contrast angiographic LVEF (six patients) were used. A LVEF of 0% was assigned to 24 patients who died within 10 days after admission without undergoing angiography. Median LVEF was 43% in the control group and 50% in the streptokinase group (p = .0001). The largest differences in median LVEF between the two treatment groups were found in patients with an anterior infarct, in patients admitted within 2 hr after onset of symptoms, and in patients in Killip class III or IV at admission (table 2) .
Effect of thrombolytic therapy on 3 month mortality.
Three month mortality was higher in patients allocated to conventional treatment (14%) than in patients allocated to thrombolytic therapy (6%, p = .006). This difference in mortality was expressed as a negative risk difference (6% -14% = -8%) produced by thrombolytic therapy. The largest reduction in 3 month mortality was observed in patients admitted within 1 hr after onset of symptoms, in patients with EST greater than 1.7 mV, in patients pretreated with intravenous streptokinase, in patients with previous myocardial infarction, and in patients in Killip class III or IV at admission ( In stepwise regression analysis the following baseline variables appeared to be relevant predictors of cumulative HBDH release, LVEF, and 3 month mortality:
EST, allocation to thrombolytic therapy, location of the infarct, and Killip class at admission. The effect of thrombolytic therapy was modified by EST, delay in admission, and Killip class on admission. Other factors, including age, gender, history of angina, participating center, and allocation to intracoronary streptokinase or intravenous and intracoronary streptokinase did not contribute to the prediction of cumulative HBDH release, LVEF, or 3 month mortality when the above-mentioned variables were included in the regression model.
The results of the regression analysis are given in table 3. At the top, the coefficients for the baseline variables predicting cumulative HBDH release, LVEF, and 3 month mortality are given. The bottom of table 3 gives additional values for predictive variables for patients allocated to thrombolytic therapy, indicating the limitation of enzymatic infarct size, the improvement in LVEF, and the reduction in 3 month mortality as a result of thrombolytic therapy. From the coefficients for the variables used in the regression analysis, the predicted effect of thrombolytic therapy on enzymatic infarct size, LVEF, and mortality can be calculated. For example, a patient with an anterior infarction was admitted 1 hr after onset of symptoms (figure 3) . The predicted improvement in LVEF as a result of thrombolysis is 9% + 2% for each millivolt of EST -3% for each hour after onset of symptoms. The risk difference for mortality after thrombolytic therapy is 3% -8% for each millivolt of EST + 2% for each hour between onset of symptoms and admission.
Since these computations are somewhat cumbersome, four subgroups of patients that can easily be recognized in clinical practice were defined: patients with IST less than 1.2 mV, those with IST of 1.2 mV or more, those with times from onset of symptoms to admission of less than 2 hr, and those with times from onset of between 2 and 4 hr. Patency rate at the end of the procedure was high in all these subsets of patients, although somewhat lower (68%) in patients with EST less than 1.2 mV who were admitted between 2 and 4 hr after onset of symptoms (figure 2). Limitation of infarct size by thrombolytic therapy was greatest in patients with EST of 1.2 mV or more and in patients admitted within 2 hr after onset of symptoms ( figure  4) 20%) . In the other subgroups 3 month mortality was below 5% in the control patients.
Calculation of enzymatic infarct size. Enzymatic infarct size can be calculated from the cumulative release of enzymes into plasma.5,9, 10 The two-compartment model used in the present study has been verified for several cardiac enzymes,'2 and takes into account the fractional catabolic rate or clearance of the enzymes from the blood. After thrombolytic therapy peak serum enzyme levels are increased due to faster washout after reperfusion. 13 14 However, the total amount of enzyme release does not change after reperfusion, '5' 16 SO invalidated by thrombolytic therapy.5' 1 In the present study HBDH release was measured because it can be computed accurately from samples taken at 12 hr intervals, whereas creatine kinase should be sampled for more frequently. The method of calculation of cumulative HBDH release used in the present study has been described in detail by Van In the Western Washington trial,17-20 mean time to initiation of streptokinase infusion was 276 min, and patients with newly formed Q waves or receiving maintenance therapy for congestive heart failure were excluded. A significant reduction in early mortality was reported, although no beneficial effect on infarct size by thallium imaging or on left ventricular function was observed. Apparently this study included many patients who would not benefit from thrombolytic therapy according to our analysis, while patients with extensive ischemia leading to left ventricular failure, who might have benefitted from thrombolytic therapy, were excluded. In two other studies the infusion of streptokinase started on average more than 5 hr after the onset of symptoms and patients with signs of cardiogenic shock were excluded. 21 22 No improvement in left ventricular function or reduction in mortality was observed, which is consistent with our observations. Among three relatively small studies beneficial effects of thrombolytic therapy were observed in only one, in which the mean time between onset of symptoms and admission was 160 min.2326 In most of these studies patients with newly formed Q waves or signs of cardiogenic shock were excluded, and these groups of patients were shown to benefit greatly from thrombolytic therapy in the present trial. 30 ST segment elevation as predictor of the effects of thrombolytic therapy. In the regression analysis enzymatic infarct size was strongly related to EST, although ST segment elevation may vary considerably over longer periods of time in patients with acute myocardial infarction..31' 32 The highest ST segment elevation is usually found within 1 hr after the onset of symptoms. In a group of patients who are already in the hospital before the onset of symptoms infarct size may be overestimated by EST. This explains why "in hospital at the onset of symptoms" was included as an independent variable in the regression model. In patients admitted after the onset of symptoms no correction was necessary for the gradual decrease in ST segment elevation with time.
Contrary to other observations,33 we noted that patients with inferior infarction and precordial ST segment depression generally had larger infarctions than patients without precordial ST segment depression. The regression coefficient for the total ST segment elevation was equal to the regression coefficient for the total precordial ST segment depression, so both were combined. Contralateral ST segment depression was not related to enzymatic infarct size in patients with anterior infarction, and therefore was not included in the regression model. 
